Novo Nordisk: What We Think of the Stock After Earnings
Published . Updated .
Market Call
Think this story will push the stock up or down over the next three trading days? Make a free call and see what other readers think. Points are play money with no cash value.
Get these market calls by email
The week's biggest market-moving stories, Congress trades and Trump posts, with the tickers they touch. Free, one email a week.
Free. We only use your email to send the digest, never sell or share it, and every email has a one-click unsubscribe link. See our privacy policy.
This report does not map to a usual set of affected companies.
Directly affected
- NVO Novo Nordisk A S-10.5% 30d
Named in this report.
Indirectly affected
- XLV Health Care Select Sector SPDR
Health Care Select Sector SPDR holds the health sector that Novo Nordisk A/S belongs to, so it often moves with news about it.
- NVS Novartis AG-0.1% 14d
Novartis AG is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- AZN AstraZeneca+12.6% 30d
AstraZeneca is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- GSK Gsk-8.1% 7d
Gsk is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- SNY Sanofi
Sanofi is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
- ROIV Roivant Sciences+3.3% 11d
Roivant Sciences is a peer of Novo Nordisk A/S in pharmaceutical preparations; rivals often move on the same news.
Price reaction, T-5 to T+3
| Ticker | T-5 | T-3 | T-1 | T0 | T+1 | T+2 | T+3 |
|---|---|---|---|---|---|---|---|
| NVO | -7.15% | -4.07% | base | after close | after close | after close | after close |
| XLV | -2.96% | -2.66% | base | after close | after close | after close | after close |
| NVS | -2.40% | -2.15% | base | after close | after close | after close | after close |
| AZN | -7.67% | -1.27% | base | after close | after close | after close | after close |
| GSK | -4.85% | -3.95% | base | after close | after close | after close | after close |
| SNY | -9.10% | -4.03% | base | after close | after close | after close | after close |
| ROIV | -1.86% | -6.10% | base | after close | after close | after close | after close |
Closing-price change versus T-1, the last close before the story. T0 to T+3 fill in after each market close. Prices: Alpaca IEX.
Novo Nordisk: What We Think of the Stock After Earnings Morningstar
Source: Morningstar
This story
| Company | When | Move | Status |
|---|---|---|---|
| AZN | three days earlier | -1.27% | final price |
| AZN | five days earlier | -7.67% | final price |
| GSK | three days earlier | -3.95% | final price |
| GSK | five days earlier | -4.85% | final price |
| NVO | three days earlier | -4.07% | final price |
| NVO | five days earlier | -7.15% | final price |
| NVS | three days earlier | -2.15% | final price |
| NVS | five days earlier | -2.40% | final price |
| ROIV | three days earlier | -6.10% | final price |
| ROIV | five days earlier | -1.86% | final price |
| SNY | three days earlier | -4.03% | final price |
| SNY | five days earlier | -9.10% | final price |
| XLV | three days earlier | -2.66% | final price |
| XLV | five days earlier | -2.96% | final price |
Congressional trades in the stocks in this story
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 10 Sep 2026. That is 56 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 31 Aug 2026. That is 66 days before publication. Filed 25 Sep 2026. View the filing.
- Rep. Scott Scott Franklin bought Novo Nordisk A S (NVO), worth $1,001 - $15,000 on 26 Aug 2026. That is 71 days before publication. Filed 17 Sep 2026. View the filing.
- Rep. Kevin Hern sold Novartis Ag (NVS), worth $15,001 - $50,000 on 27 Aug 2026. That is 70 days before publication. Filed 25 Sep 2026. View the filing.
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
How solid “Novo Nordisk: What We Think of the Stock After Earnings” looks
38 out of 100
“Novo Nordisk: What We Think of the Stock After Earnings” scores 38 out of 100. The score uses 3 sources.